CTLA4 and vulva cancer: In the recurrent and metastatic setting there is an ongoing Ph II study evaluating the safety and efficacy of an anti PD-1 and CTLA-4 bispecific antibody (AK104), and the PIERCE trial evaluating Pembrolizumab in Combination with Lenvatinib in patients With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy.